2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claims
2022
Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry
Friedman DJ, Pierre D, Wang Y, Gambone L, Koutras C, Segawa C, Farb A, Vemulapalli S, Varosy PD, Masoudi FA, Lansky A, Curtis JP, Freeman JV. Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry. American Heart Journal 2022, 254: 102-111. PMID: 36007567, DOI: 10.1016/j.ahj.2022.08.006.Peer-Reviewed Original ResearchConceptsEnd point adjudicationCEC adjudicationEnd pointLarge registriesClinical trialsNational Cardiovascular Data RegistryMajor vascular complicationsU.S. National RegistryPost-discharge eventsAgreement rateMajor bleedingNeurologic eventsVascular complicationsNational registryEvent adjudicationData registryRegistryCommittee's evaluationsPercent agreementGold standardAgreement thresholdHospitalTrialsFurther confirmationBleedingPatient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials
Friedman DJ, Du C, Wang Y, Agarwal V, Varosy PD, Masoudi FA, Holmes DR, Reddy VY, Price MJ, Curtis JP, Freeman JV. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC Cardiovascular Interventions 2022, 15: 950-961. PMID: 35512918, PMCID: PMC9370831, DOI: 10.1016/j.jcin.2022.02.029.Peer-Reviewed Original ResearchConceptsRegistry patientsHemorrhagic stroke riskIschemic strokeWarfarin patientsTrial patientsStroke riskLAAO patientsClinical practiceMore pericardial effusionsPeriprocedural ischemic strokePropensity-matched analysisAtrial appendage occlusionCox proportional hazardsPatient-level dataFine-Gray modelMore comorbiditiesPROTECT AFNoncardiovascular deathPericardial effusionHemorrhagic strokeAppendage occlusionDevice implantationTrial criteriaClinical trialsSimilar risk
2021
B-PO03-155 OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN IN CONTEMPORARY CLINICAL PRACTICE COMPARED WITH CLINICAL TRIALS: A POOLED ANALYSIS OF PROTECT-AF, PREVAIL, AND THE NCDR LAAO REGISTRY
Friedman D, Du C, Agarwal Y, Varosy P, Masoudi F, Curtis J, Freeman J. B-PO03-155 OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN IN CONTEMPORARY CLINICAL PRACTICE COMPARED WITH CLINICAL TRIALS: A POOLED ANALYSIS OF PROTECT-AF, PREVAIL, AND THE NCDR LAAO REGISTRY. Heart Rhythm 2021, 18: s252. DOI: 10.1016/j.hrthm.2021.06.628.Peer-Reviewed Original ResearchPrognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Kazi D, Shen C, Yeh RW. Prognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. Journal Of The American Heart Association 2021, 10: e018744. PMID: 33682431, PMCID: PMC8174225, DOI: 10.1161/jaha.120.018744.Peer-Reviewed Original ResearchConceptsUnadjusted mortality ratesIschemic eventsDAPT studyMortality rateEnd pointCox proportional hazards modelPercutaneous coronary interventionProportional hazards modelCardiovascular clinical trialsTrial adjudicationBleeding eventsCathPCI RegistryCoronary interventionCoronary stentingSimilar prognosisPrognostic significanceClinical eventsClinical trialsMedicare claimsAdministrative claimsMortality riskHazards modelPatientsPrognosisDeathComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2019
Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement
Strom JB, Zhao Y, Faridi KF, Tamez H, Butala NM, Valsdottir LR, Curtis J, Brennan JM, Shen C, Boulware M, Popma JJ, Yeh RW. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation Cardiovascular Interventions 2019, 12: e008231. PMID: 31694411, PMCID: PMC7212938, DOI: 10.1161/circinterventions.119.008231.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic ValveAortic Valve StenosisBrain IschemiaClinical Trials as TopicDatabases, FactualFemaleHeart Valve Prosthesis ImplantationHumansIschemic Attack, TransientMaleMedicareRisk AssessmentRisk FactorsStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsNegative predictive valueAortic valve replacementCerebrovascular eventsInternational ClassificationPositive predictive valuePredictive valueValve replacementNinth RevisionClinical trialsTenth RevisionBilling codesKaplan-Meier estimatesMedicare inpatient claimsSURTAVI trialClinical event adjudicationDevastating complicationIschemic strokeNeurological eventsCerebrovascular diseaseBilling claimsInpatient claimsEvent adjudicationAdministrative claimsHigh riskTrial participants
2017
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators
Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O’Conner C, Levy WC. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. Journal Of The American College Of Cardiology 2017, 69: 2606-2618. PMID: 28545633, PMCID: PMC5502749, DOI: 10.1016/j.jacc.2017.03.568.Peer-Reviewed Original ResearchConceptsSeattle Heart Failure ModelSeattle Proportional Risk ModelNational Cardiovascular Data RegistryPrimary prevention ICDsHeart failureSudden deathCause mortalitySurvival benefitMultivariable Cox proportional hazards regressionCox proportional hazards regressionProportional riskProportional hazards regressionRecent clinical trialsHeart failure modelProportional risk modelControl patientsOverall survivalVentricular arrhythmiasHazards regressionICD benefitClinical trialsCardioverter defibrillatorLarge cohortHigh riskData registry
2015
Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?
Heidenreich PA, Tsai V, Bao H, Curtis J, Goldstein M, Curtis L, Hernandez A, Peterson P, Turakhia MP, Masoudi FA. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Failure 2015, 3: 497-504. PMID: 25982109, DOI: 10.1016/j.jchf.2015.01.012.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionICD implantationOlder patientsTrial criteriaNew York Heart Association functional class IIIAge groupsSocial Security Death IndexPatients age 85Receipt of CRTFunctional class IIICardiac resynchronization therapyVentricular ejection fractionClinical trial criteriaDifferent age groupsPatient ageEjection fractionICD RegistryImproved survivalPrimary outcomeResynchronization therapyTherapy useDeath IndexMean ageClinical trialsRegistry dataGender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR)
Russo AM, Daugherty SL, Masoudi FA, Wang Y, Curtis J, Lampert R. Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). American Heart Journal 2015, 170: 330-338. PMID: 26299231, PMCID: PMC4768728, DOI: 10.1016/j.ahj.2015.02.025.Peer-Reviewed Original ResearchConceptsNational Cardiovascular Data RegistryPrimary preventionHF readmissionCause readmissionHospital dischargeICD implantationHeart failurePrimary prevention implantable cardioverter-defibrillator (ICD) implantationDual-chamber ICD implantationImplantable cardioverter defibrillator implantationPatients 65 yearsAdvanced heart failureProcedure-related complicationsCardioverter-defibrillator implantationDevice-related complicationsSudden cardiac deathHigh-risk individualsDual-chamber ICDGreater comorbidityBaseline characteristicsOlder patientsCardiac deathProcedural complicationsWorse outcomesClinical trials
2014
Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women
Zeitler EP, Hellkamp AS, Fonarow GC, Hammill SC, Curtis LH, Hernandez AF, Al-Khalidi HR, Curtis JP, Heidenreich PA, Anstrom KJ, Peterson ED, Mark DB, Hammill BG, Sanders GD, Al-Khatib SM. Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC Heart Failure 2014, 3: 159-167. PMID: 25543969, PMCID: PMC4461749, DOI: 10.1016/j.jchf.2014.09.006.Peer-Reviewed Original ResearchConceptsPrimary prevention implantable cardioverter defibrillatorsImplantable cardioverter defibrillatorHeart failureCardioverter defibrillatorOlder womenNational Cardiovascular Data Registry ICD RegistryLeft ventricular dysfunctionSignificant survival benefitSurvival of womenYears of ageMedicare claims databaseEligible patientsCause mortalityPrimary endpointVentricular dysfunctionSurvival benefitICD RegistryClaims databaseHeart failure databaseLonger survivalClinical trialsPropensity score methodsPatientsWomenSurvivalClinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure
Khazanie P, Hammill BG, Qualls LG, Fonarow GC, Hammill SC, Heidenreich PA, Al-Khatib SM, Piccini JP, Masoudi FA, Peterson PN, Curtis JP, Hernandez AF, Curtis LH. Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. Circulation Heart Failure 2014, 7: 926-934. PMID: 25227768, PMCID: PMC4244212, DOI: 10.1161/circheartfailure.113.000838.Peer-Reviewed Original ResearchConceptsAcute Decompensated Heart Failure National RegistryImplantable Cardioverter-Defibrillator RegistryHeart failureMedical therapyCardiovascular readmissionCause readmissionQRS durationNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryLeft ventricular ejection fractionCox proportional hazards modelHistorical control cohortOptimal medical therapyCardiac resynchronization therapyVentricular ejection fractionProportional hazards modelMultivariable adjustmentEjection fractionICD RegistryResynchronization therapyClinical effectivenessControl cohortNational registryClinical trialsLower riskHazards model
2013
QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy
Peterson PN, Greiner MA, Qualls LG, Al-Khatib SM, Curtis JP, Fonarow GC, Hammill SC, Heidenreich PA, Hammill BG, Piccini JP, Hernandez AF, Curtis LH, Masoudi FA. QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. JAMA 2013, 310: 617-626. PMID: 23942680, DOI: 10.1001/jama.2013.8641.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBundle-Branch BlockCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesCardiovascular DiseasesCohort StudiesElectrocardiographyFee-for-Service PlansFemaleHeart FailureHumansMaleMedicarePatient ReadmissionRetrospective StudiesRiskTreatment OutcomeUnited StatesConceptsLeft bundle branch blockCRT-D implantationCardiac resynchronization therapyHeart failure readmissionQRS durationCause mortalityICD RegistryResynchronization therapyUnadjusted ratesMedicare beneficiariesNational Cardiovascular Data Registry ICD RegistryClinical practiceBundle branch block morphologyCause readmission rateRetrospective cohort studyLonger QRS durationBundle branch blockService Medicare beneficiariesCause readmissionCohort studyCRT-defibrillatorOlder patientsReadmission ratesHeart failureClinical trialsSurvival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials
Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials. JAMA 2013, 309: 55-62. PMID: 23280225, PMCID: PMC3638257, DOI: 10.1001/jama.2012.157182.Peer-Reviewed Original ResearchConceptsPrimary prevention ICDsPrimary prevention clinical trialsTrial-eligible patientsSurvival of patientsPrevention clinical trialsClinical trialsICD RegistrySCD-HeFTClinical practiceRegistry patientsMADIT-IISimilar patientsNational Cardiovascular Data Registry ICD RegistryPrimary prevention implantable cardioverter defibrillatorsSurvival rateImplantable cardioverter-defibrillator therapyMADIT II criteriaMADIT II patientsSCD-HeFT criteriaCardioverter-defibrillator therapyClinical trial patientsLarge national registryRandomized clinical trialsProportional hazards modelImplantable cardioverter defibrillator
2011
Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries
Nallamothu BK, Gurm HS, Ting HH, Goodney PP, Rogers MA, Curtis JP, Dimick JB, Bates ER, Krumholz HM, Birkmeyer JD. Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries. JAMA 2011, 306: 1338-1343. PMID: 21954477, PMCID: PMC3208144, DOI: 10.1001/jama.2011.1357.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAtherosclerosisCarotid StenosisCenters for Medicare and Medicaid Services, U.S.Clinical CompetenceFee-for-Service PlansFemaleHospital MortalityHumansInsurance CoverageMaleMedicarePhysiciansQuality of Health CareRetrospective StudiesStentsStrokeTime FactorsTreatment OutcomeUnited StatesConceptsAnnual operator volumeCarotid stentingOperator volumeMedicare beneficiariesNational coverage decisionHigh riskOperator experienceStudy periodThirty-day mortalityEmbolic protection devicesHigh-volume operatorsLow-volume operatorsService Medicare beneficiariesLow annual volumeMultivariable adjustmentOlder patientsRate of failureClinical trialsCoverage decisionsObservational studyMAIN OUTCOMEPatientsClinical practiceStentingMore procedures
2005
The Impact of Clinical Trials on the Use of Hormone Replacement Therapy
Kim N, Gross C, Curtis J, Stettin G, Wogen S, Choe N, Krumholz HM. The Impact of Clinical Trials on the Use of Hormone Replacement Therapy. Journal Of General Internal Medicine 2005, 20: 1026-1031. PMID: 16307628, PMCID: PMC1490267, DOI: 10.1111/j.1525-1497.2005.0221.x.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionAgedClinical Trials as TopicFemaleHormone Replacement TherapyHumansInformation DisseminationInsurance, Pharmaceutical ServicesLongitudinal StudiesMiddle AgedPatient Acceptance of Health CarePractice Patterns, Physicians'Retrospective StudiesTreatment RefusalUnited StatesConceptsWomen's Health InitiativeHormone replacement therapyHRT useHRT discontinuationReplacement therapyHealth initiativesHormone replacement therapy useLocal practice patternsHRT prescriptionHRT usersMarked regional variationPrescription fillingTherapy useClinical behaviorClinical trialsPractice patternsSubstantial geographic variationTrial publicationsDiscontinuationHealth databasesTrial dataAge groupsRapid effectsWest South CentralTrial results
2004
National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2004, 110: 724-731. PMID: 15289383, DOI: 10.1161/01.cir.0000138934.28340.ed.Peer-Reviewed Original ResearchConceptsACE inhibitor prescriptionAngiotensin receptor blockersVentricular systolic dysfunctionHeart failureACE inhibitorsInhibitor prescriptionSystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionAngiotensin converting enzyme (ACE) inhibitorsSerum creatinine levelsACE inhibitor useCreatinine levelsHospital factorsInhibitor useReceptor blockersSerum creatininePatient genderClinical trialsTherapeutic substitutionLower riskEnzyme inhibitorsLower mortalityPatientsSecondary analysis
2002
β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction
Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction. JAMA 2002, 288: 351-357. PMID: 12117400, DOI: 10.1001/jama.288.3.351.Peer-Reviewed Original ResearchConceptsBeta-blocker therapySexual dysfunctionDepressive symptomsSymptoms of depressionAdverse eventsHeart failureMyocardial infarctionSignificant annual increaseAdditional reportsLipid solubilityAdverse effectsWithdrawal of therapyΒ-blocker therapyPatient-reported symptomsNumber of patientsEnglish-language articlesInclusion of trialsPlacebo groupMortality benefitRandomized trialsStudy treatmentCardiac patientsPlacebo controlRisk of fatigueClinical trialsClinical trials do not support strong association of beta-blocker therapy with fatigue, depression, or sexual dysfunction
Ko D, Hebert P, Coffey C, Sedrakyan A, Curtis J, Krumholz H. Clinical trials do not support strong association of beta-blocker therapy with fatigue, depression, or sexual dysfunction. Journal Of The American College Of Cardiology 2002, 39: 440. DOI: 10.1016/s0735-1097(02)81978-7.Peer-Reviewed Original Research